LINC02987: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

Target Name: LINC02987

NCBI ID: G101927151

LINC02987

Other Name(s): Long intergenic non-protein coding RNA 2987, transcript variant 7 | long intergenic non-protein coding RNA 2987

LINC02987: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

LINC02987 is a long intergenic non-protein coding RNA (lncRNA) with a length of approximately 2987 nucleotides. It is located between the intron 19 and exon 20 of the human genomic sequence and is expressed in various cell types. The function and regulation of lncRNA are still poorly understood, but recent studies have suggested that it may play a crucial role in various biological processes, including cell growth, apoptosis, and development. As a result, lncRNA has been identified as a potential drug target in the field of neurodegenerative diseases.

Disease-Related Functions of LINC02987

LINC02987 has been shown to be involved in several disease-related functions. For instance, it has been associated with various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These associations are based on the fact that lncRNA is expressed in the brain and is involved in the development and progression of these disorders.

Additionally, lncRNA has been shown to play a role in cell apoptosis. Apoptosis is a natural mechanism of cell death that is regulated by various factors, including the expression of pro-apoptotic and anti-apoptotic proteins. Studies have shown that lncRNA can induce cell apoptosis in various cell types and that its expression is often associated with the stress response.

Furthermore, lncRNA has also been shown to be involved in cell proliferation. Several studies have shown that lncRNA can promote the growth and proliferation of various cell types, including cancer cells. This is because lncRNA contains elements that are similar to those found in pro-growth factors, such as the NF-kappa signaling pathway.

Potential Therapeutic Applications

The potential therapeutic applications of lncRNA are vast and varied. One of the most promising therapeutic strategies is to target lncRNA itself with small molecules or antibodies to disrupt its function and reduce its expression. This approach has been shown to be effective in animal models of several neurological disorders, including Alzheimer's disease and Parkinson's disease.

Another approach to targeting lncRNA is to use drugs that specifically target its downstream targets. LncRNA can be regulated by various post-transcriptional modifications, such as RNA binding proteins (PtPs) and RNA-protein interactions. Therefore, drugs that target these modifications could be useful in reducing lncRNA expression.

Additionally, some researchers have suggested that lncRNA could be used as a biomarker for certain neurological disorders. For instance, lncRNA expression has been shown to be elevated in the brains of individuals with Alzheimer's disease, and this increase in expression has been associated with the severity of the disease. Therefore, measuring lncRNA expression levels could be a promising biomarker for Alzheimer's disease.

Conclusion

In conclusion, lncRNA like LINC02987 has been shown to be involved in several disease-related functions, including cell growth, apoptosis, and development. Its potential as a drug target is currently being investigated, and several studies have shown that it has the potential to be a effective therapeutic strategy for the treatment of neurological disorders. Further research is needed to fully understand the functions and regulation of lncRNA and to develop safe and effective drugs that target it.

Protein Name: Long Intergenic Non-protein Coding RNA 2987

The "LINC02987 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02987 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets